Finally, based on the available evidence on the effect of biological drugs and small molecules for managing moderate‐to‐severe Crohn's disease in adults, we recommend incorporating novel inhibitors of IL‐23 as second‐line alternatives, especially for patients who have previously failed other biologic treatments. Here, IL23A is linked to Crohn disease.